Estrella Immunopharma (NASDAQ:ESLA) Trading Up 26.5% – Here’s Why

Shares of Estrella Immunopharma, Inc. (NASDAQ:ESLA) were up 26.5% on Tuesday . The company traded as high as $1.95 and last traded at $1.72. Approximately 1,226,373 shares changed hands during trading, an increase of 2,097% from the average daily volume of 55,822 shares. The stock had previously closed at $1.36.

Analyst Ratings Changes

Several research firms recently issued reports on ESLA. Weiss Ratings restated a “sell (d-)” rating on shares of Estrella Immunopharma in a research note on Wednesday, January 28th. Wall Street Zen upgraded Estrella Immunopharma from a “sell” rating to a “hold” rating in a research report on Saturday, January 31st. Finally, D. Boral Capital restated a “buy” rating and set a $8.00 price objective on shares of Estrella Immunopharma in a research report on Monday, February 9th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $8.00.

Estrella Immunopharma Stock Up 26.5%

The firm has a 50 day moving average price of $1.17 and a two-hundred day moving average price of $1.50. The company has a market cap of $73.38 million, a price-to-earnings ratio of -4.91 and a beta of 0.58.

Institutional Investors Weigh In On Estrella Immunopharma

Several large investors have recently added to or reduced their stakes in ESLA. Quadrature Capital Ltd acquired a new stake in Estrella Immunopharma during the fourth quarter worth approximately $43,000. State Street Corp boosted its position in shares of Estrella Immunopharma by 93.5% during the fourth quarter. State Street Corp now owns 43,252 shares of the company’s stock valued at $67,000 after buying an additional 20,900 shares during the last quarter. XTX Topco Ltd boosted its position in shares of Estrella Immunopharma by 376.9% during the fourth quarter. XTX Topco Ltd now owns 49,472 shares of the company’s stock valued at $77,000 after buying an additional 39,099 shares during the last quarter. Marshall Wace LLP purchased a new position in shares of Estrella Immunopharma during the fourth quarter valued at approximately $88,000. Finally, Geode Capital Management LLC lifted its holdings in Estrella Immunopharma by 8.2% during the fourth quarter. Geode Capital Management LLC now owns 109,808 shares of the company’s stock worth $171,000 after acquiring an additional 8,318 shares during the period. Institutional investors and hedge funds own 0.35% of the company’s stock.

About Estrella Immunopharma

Estrella Immunopharma, Inc, a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103.